Vaccination with Sputnik V launched in India
- Details
- Category: Business
![Russian Direct Investment Fund (RDIF) Russian Direct Investment Fund (RDIF)](/images/logo/rdif.png)
Sputnik V has become the first foreign-made vaccine that is used in India contributing to the world’s largest COVID-19 vaccination campaign.
Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates high immunogenicity against virus variants in preclinical study
- Details
- Category: Business
![CureVac CureVac](/images/logo/curevac.png)
Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate
- Details
- Category: Business
![Novavax, Inc. Novavax, Inc.](/images/logo/novavax.png)
Moderna announces emergency use listing granted by the World Health Organization for its COVID-19 vaccine
- Details
- Category: Business
![Moderna, Inc. Moderna, Inc.](/images/logo/moderna.png)
Moderna announces additional investments to increase global supply for COVID-19 vaccine to up to 3 billion doses in 2022
- Details
- Category: Business
![Moderna, Inc. Moderna, Inc.](/images/logo/moderna.png)
CureVac Swiss AG initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic
- Details
- Category: Business
![CureVac CureVac](/images/logo/curevac.png)
Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
- Details
- Category: Business
![Valneva Valneva](/images/logo/valneva.png)
More Pharma News ...
- Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
- Pfizer and BioNTech request regulatory agencies expand emergency use of their COVID-19 vaccine to adolescents
- Valneva reports positive Phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001
- Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study
- BioNTech provides update on vaccine production status at Marburg manufacturing site
- NIAID statement on AstraZeneca vaccine and AstraZeneca update
- Bharat Biotech announces Phase 3 results of COVAXIN®: India's first COVID-19 vaccine demonstrates interim clinical efficacy of 81%